CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market sale Director sold 20,000 shares at $2.85 ($57,086)
- 4 Open-market buy 10% owner bought 22,319 shares at an average $2.05 ($45,782)
- 4 Open-market buy 10% owner bought 19,681 shares at an average $1.92 ($37,814)
- 4 Open-market buy 10% owner bought 145,000 shares at $2.57 ($373,114)
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion 10% owner acquired 100,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
- 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
- 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
- 4 Exercise or conversion Director acquired 47,222 shares (option exercise)
- 4 Open-market buy 10% owner bought 5,000 shares at $2.70 ($13,492)
- 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
- 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
- 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
- 4 Exercise or conversion Director acquired 2,778 shares (option exercise)
- 4 Exercise or conversion Director acquired 100,000 shares (option exercise)
- 4 Exercise or conversion 10% owner acquired 150,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 6,000 shares at $2.91 ($17,430)
- 4 Open-market buy 10% owner bought 4,000 shares at $3.29 ($13,170)
Page 7 of 9 · 170 filings